Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles

To cite this article: Meir Goldsmith et al 2018 Nano Futures 2 045003

View the article online for updates and enhancements.
Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles

Meir Goldsmith1,2,3,4,5, Lilach Abramovitz1,2,3,4,5, Hila Braunstein2, Mia Horowitz2,6 and Dan Peer1,2,3,4,5,6,6

1 Laboratory of Precision NanoMedicine, Tel Aviv University, Tel Aviv 69978, Israel
2 Department of Cell Research & Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
3 Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel
4 Center for Nanoscience and Nanotechnology, and Tel Aviv University, Tel Aviv 69978, Israel
5 Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel
6 Authors to whom any correspondence should be addressed.
E-mail: horwitzm@post.tau.ac.il and Peer@tauex.tau.ac.il

Keywords: lipid nanoparticles, case, brain delivery

Abstract

Gaucher disease (GD), the most prevalent genetic lysosomal storage disease, is characterized by the accumulation of glucosylceramide, mainly in monocyte-derived cells, due to deficient activity of lysosomal acid-β-glucocerebrosidase (GCase). The disease is heterogeneous and may vary from a very mild visceral disease to a severe neuronopathic disease, with very early death during the first years of life. Two therapeutic modalities are in use today; enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Neither of the two modalities are applicable for patients with the neuronopathic forms of GD. While the infused enzyme in ERT cannot cross the blood–brain-barrier, SRT is not suitable for young patients. Herein, we investigated novel approaches to deliver recombinant GCase (rGCase) into the brain using lipid nanoparticles (LNPs). These LNPs were composed of a mixture of negative, positive and zwitterion phospholipids and were delivered intranasally into the brains of mice. A quantitative analysis performed intranasally in mice revealed a dramatic accumulation of the enzyme that was formulated into the LNPs in the brains of the mice (3.91% ± 0.3% injected dose (ID)/mg tissue) versus the free enzyme (0.29% ± 0.07, % ID/mg tissue). The administrated particle-delivered enzymes were able to enter the brain parenchyma and accumulate in the CD11b+ cells, which are the target cells in GD. When supplied to GD-derived skin fibroblasts, a 35% ± 1.2 increase in intracellular GCase activity was measured only with the LNP-encapsulated enzyme. This strategy may pave the way for novel therapeutic modalities to treat GD and other diseases such as Alzheimer’s and Parkinson’s.

1. Introduction

Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by defects in the GBA1 gene, encoding acid β-glucocerebrosidase (GCase) [1, 2]. Decreased GCase activity leads to the accumulation of glucosylceramides, mainly in monocyte-derived lineages [3]. GCase accumulation can manifest in a variety of phenotypes ranging from a perinatal lethal form to an asymptomatic form [4, 5]. Due to its heterogeneity, GD has been divided into three clinical types based on disease phenotype, progression and the presence or absence of neurological involvement. The most prevalent type, 1 GD, is essential non-neuropathic since it lacks primary central nervous system (CNS) involvement. Patients with this type of disease may develop anemia, thrombocytopenia, hepatosplenomegaly, skeletal abnormalities, interstitial lung disease and pulmonary hypertension [6]. Type 2 GD is an acute neuropathic form with severe neurological manifestations and survival is limited to the first years of life. Type 3 GD is also characterized by neurological involvement but neurological
symptoms generally appear later in life in comparison to type 2, and include abnormal eye movements, ataxia, seizures, and dementia, with patients surviving until their 30s or 40s [7].

To date there are two therapeutic modalities for GD, enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). ERT has emerged as the standard of care for type I GD [8, 9]. Over two decades since the introduction of this therapy [10], it has become clear that many of the symptoms and signs of visceral GD respond adequately to ERT [11]. Despite its great success, ERT also has disadvantages, including costly manufacture, inconvenience of the intravenous infusions and the inability of the intravenously administered enzyme to cross the blood–brain barrier (BBB).

In the present study, we aimed to develop an approach, which will facilitate the administration of recombinant GCase (rGCase) into the CNS while bypassing the BBB. In order to achieve this, we devised a carrier that encapsulated the rGCase and utilized an alternative delivery method into the brain. We focused on lipid nanoparticles (LNPs) as the vehicles for protein delivery since LNPs have been shown to successfully encapsulate a wide variety of proteins including superoxide dismutase [12], acetylcholinesterase [13] and myoglobin [14] and were successful in protecting protein cargo from environmental factors and degradation [15–18]. LNPs also facilitate tissue and cellular penetration primarily by the endocytic pathway, due to the lipophilic nature of LNPs [19]. Furthermore, LNPs have been used for the transport of anticancer and anti-inflammatory drugs into the brain by intravenous [20] or intracerebral delivery [21]. LNPs are easily modified by changing the composition of the phospholipids. Such modifications enable a wide range of possibilities to suit encapsulation of different proteins and facilitate cellular penetration [22].

Crossing the BBB and reaching the desired destination in the brain depends not only on the composition of the carriers but also on the routes of administration. Herein we focused on the intranasal (IN) delivery route. IN mediated delivery of proteins has emerged as a non-invasive, safe and effective method to target peptides and proteins to the CNS, bypassing the BBB, minimizing systemic exposure and limiting peripheral adverse effects [23].

2. Materials and methods

2.1. LNP preparation

1,2-Dilauroyl-sn-glycero-3-phosphorylethanolamine (DLPE), 1,2-Dilauroyl-sn-glycero-3-phosphorylglycerol (DLPG) and 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) were purchased from Avanti Polar Lipids Inc. (AL USA). The lipids were dissolved in ethanol and mixed together at three different molar ratios, either 60:40 (DLPE/DLPG), 57.5:37.5:5 (DLPE/DLPG/DOTMA) or 52.5:32.5:15 (DLPE/DLPG/DOTMA). The solution was evaporated until dry under a reduced pressure in a Buchi Rotary Evaporator Vacuum System (Flawil, Switzerland) and hydrated with either 50 mM citrate buffer (pH 6) or 50 mM citrate buffer (pH 6) with rGCase (1 mg ml⁻¹ rGCase) to a final concentration of 5 mg ml⁻¹ lipids and shaken for 2 h at room temperature. After being kept overnight at 4 °C the LNPs were extruded through a Lipex Extrusion Device (Northern lipids, Vancouver, Canada), operated under nitrogen pressures of 200–500 psi with a filter pore size of 400 nm (Whatman Inc., UK). The LNPs were dialyzed three times in acetate buffer (pH = 6, 50 mM) using the Float-A-Lyzer 1000 kD dialysis system (Spectrum Labs, CA, USA) to remove unencapsulated rGCase. For fluorescent labeling of the rGCase we used the Alexa-647 labeling kit #120173 from molecular probes (molecular probes, Thermo Fisher Scientific, MA, USA) in accordance with the manufacturer’s protocol. The final protein to fluorophore ratio was 1:3.6 as determined by the nanodrope ND-2000 UV–vis spectrophotometer assessment (Thermo Fisher Scientific, MA, USA).

2.2. rGCase radiolabeling

Recombinant glucocerebroside was tritiated in the presence of a palladium-charcoal catalyst as previously shown [24] glucocerebroside activity was found to be 4.3 × 10⁶ dpm/nmol by thin-layer chromatography. [3H] Glucocerebroside (0.2 × 10⁶–4 × 10⁶ dpm, 0.047–0.093 nmol), 25 µg Triton X-100, 93 nmol sodium taurocholate, and 28 nmol palmitoylglucocerebroside were solubilized as described above, in 50–1 1.0 mol l⁻¹ sodium citrate buffer (pH 5.6).

2.3. Protein encapsulation efficiency

LNPs with or without rGCase were incubated in PBS containing 1% sodium deoxycholate. After 30 min of agitation the LNPs were centrifuged three times in a 10 k centrifcon (Millipore Ireland BV). The discarded liquid was replaced with PBS 1% sodium deoxycholate. The samples were incubated for 10 min between each centrifugation. The LNP remanences were dialyzed three times in 12 kD dialysis tubes (GEBA, Israel) in PBS to remove the sodium deoxycholate.
Protein levels were evaluated with the BCA protocol (Pierce, Thermo Fisher Scientific) in accordance with manufacturer’s instructions. Free GCase was used to create the standard curve.

2.4. LNP size distribution and zeta potential measurements
LNP size distribution and zeta potential were measured on a Malvern Zetasizer Nano ZS Zeta Potential and DLS instrument (Malvern Instruments, Southborough, MA, USA) using the automatic algorithm mode and analyzed with the PCS 1.32a. All size measurements were done in 50 mM, pH 6 acetate buffer, at room temperature.

2.5. Electron microscopy
The structure of the LNPs with or without rGCase was investigated using TEM. Samples were adsorbed on Formvar/carbon-coated grids and negatively stained with 2% aqueous uranyl acetate. Samples were examined using a Jeol 1200EX TEM (Jeol, Japan).

2.6. Internalization assays
All single cell suspensions were obtained with the MACS Dissociator (Miltenyl Biotec) using the Neural Tissue Dissociation Kit (Miltenyl Biotec) according to manufacturer’s instructions. Myelin removal was performed by centrifugation in a percoll gradient (Sigma, Israel).

For \textit{in vivo} LNP administration: single cell suspensions from mouse brains were seeded on 35 mm plates (IBIDI GmbH, Germany) and grown in RPMI medium supplemented with antibiotics, L-Glutamine and 10% fetal calf serum (Biological industries, Beit Haemek, Israel). After 24 h the cells were exposed to LNPs in serum-free medium for 2 h at 37 °C in a humidified atmosphere with 5% CO₂, and subsequently the cells were washed twice with PBS.

For \textit{in vitro} administration of the LNPs: single cell suspensions from treated and untreated mice were seeded on 35 mm plates (IBIDI GmbH, Germany) in PBS and were kept at 4 °C.

Prior to confocal microscopy, the cells were incubated with 488-Alexa conjugated anti-CD11b antibodies (BioLegend), with LysoTracker™ Red DND-99 (Thermo Fisher Scientific) as a lysosome marker and with Hoechst (SIGMA, Israel) for nuclear staining. Confocal microscope images were obtained on live cells using the Nikon Eclipse C2 configured with a NI-E microscope and processed with NIS-elements software using X60 objective magnification (Nikon).

2.7. Mice
The mice were housed and maintained in laminar flow cabinets under specific pathogen-free conditions in the animal quarters of Tel Aviv University and in accordance with current regulations and standards of the Israel Ministry of Health. All animal protocols were approved by Tel Aviv University Institutional Animal Care and Use Committee.

2.8. \textit{In vivo} administration, radioactivity analysis and IVIS imaging
Eight week old BALB/c female mice (Envigo Laboratories) were anesthetized with a subcutaneous injection of Ketamine/Xylazine solution (100 mg kg\(^{-1}\) Ketamine, 10 mg kg\(^{-1}\) Xylazine). Free rGCase, enzyme-free LNPs or encapsulated rGCase (1 mg ml\(^{-1}\)) were administered intranasally at a volume of 25 μl/animal, alternating between the nostrils. After administration the mice were left to recuperate before being returned to their cage. \textit{In vivo} imaging was performed using the IVIS 2000 \textit{in vivo} imaging system (Caliper Life Sciences, Hopkinton, MA, USA). For radioactivity analysis, free \(^3^H\)-rGCase was assayed using an EnVision Multimode Plate Reader (PerkinAlmer).

2.9. Cell model for GD
Human primary skin fibroblasts (cultured fibroblasts) were from NIGMS Human Genetic Cell Repository (cell lines: GM8760, L444P/L444P and GM877, L444P/RecNciI). The cells were grown in DMEM supplemented with 20% FBS (Biological Industries, Beit Haemek, Israel), at 37 °C in the presence of 5% CO₂.

2.10. Enzymatic activity
Confluent primary skin fibroblasts incubated for 4 h with 100 μg of different formulations of rGCase were washed twice with ice-cold PBS and collected in 150 μl sterile water. Cell lysates, containing 40 μg of protein, were assayed for GCase activity in 0.2 ml of 100 mM potassium phosphate buffer, pH 4.5, containing 0.15% Triton X-100 (Sigma, Israel) and 0.125% taurocholate (Calbiochem, La Jolla, CA, USA) in the presence of 1.5 mM 4-MUG (Genzyme Corp. Boston, MA, USA) for 1 h at 37 °C. The reaction was stopped by the addition of 0.5 ml of stop solution (0.1M glycine, 0.1M NaOH, pH10) and the amount of 4-methyl-umbeliferone (4-MU)
was quantified using a Perkin Elmer Luminescence Spectrometer LS 50 (excitation length: 340 nm; emission: 448 nm).

2.11. Statistical analysis
All data are expressed as a mean with SEM in animals and with SD for in vitro and physicochemical characterization of the delivery system. The comparison of the two experimental groups was performed using two-sided Student t-test. Analyses were performed with Prism 7 (Graphpad Software). Differences are labeled n.

3. Results
3.1. Preparation and characterization of lipid NPs containing rGCase
Since the accumulation of glucosylceramides characterizes macrophage derived cells, it is obvious that microglia cells are the target for ERT in neuronopathic GD [25, 26]. Although microglia and other macrophage cells readily phagocytose LNPs [27], we wanted to augment this processes in order to improve protein delivery. Previous reports have demonstrated that phagocytosis can be amplified by altering the size and charge of the particle. For example, by increasing the negative charge of the LNPs, superior phagocytosis was observed [27, 28]. Based on this finding we designed our nanocarriers to include the phospholipid DLP, which is negatively charged and is known to facilitate macrophage phagocytosis [27]. We also used the lipid DLPE, which is known to destabilize the particles and enhance penetration into cells [29, 30]. Additional formulations that were examined incorporated the cationic lipid DOTMA. We chose to use DOTMA as the permanent charged cationic lipid, as it has been shown to enable cellular penetration and enhance drug delivery [31]. Intracellular targeting is not a concern for ERT in GD as phagocytosed particles are quickly shuttled to the lysosome [32], which is the intracellular site of action of GCase in normal cells.

rGCase was entrapped within LNPs constructed of the lipids DLPE and DLP, at a molar ratio of 3:2, with or without the cationic lipid DOTMA (5% and 15%), as detailed in the Materials and Methods section (section 2). The particles were analyzed for size distribution using dynamic light scattering (DLS) and zeta potential using a zeta sizer (table 1).

GCase encapsulation in all particle formulations showed significant increase in the zeta potential to a zeta of $\sim -75$ mv. This increase in zeta potential coupled with the low encapsulation efficiency (of about 10%) could indicate that some of the GCase was not entrapped within the lipid bilayer but was attached to the surface of the particle as a protein corona; a similar phenomenon of zeta change due to protein corona formation has been documented with other proteins [33, 34]. In addition, such a high zeta potential indicates that the particle will not aggregate. To further elucidate the ultrastructure of the particles, we used transmission electron microscopy (TEM) analysis. The captured images revealed that the particles were of circular shape as expected, with high homogeneity. The size measurement of the particles was in good agreement with the DLS analysis (figure 1). The LNPs without the rGCae had globular shapes and round surfaces whereas the LNPs containing the rGCae exhibited flower-like particles.

Table 1. Physicochemical and structural analysis of lipid nanoparticles (LNPs). (A) Hydrodynamic diameters and zeta potential measurements of the different LNPs. (B) Enzyme encapsulation within LNPs and enzymatic activity relative to free enzyme.

<table>
<thead>
<tr>
<th>(A)</th>
<th>LNP—lipid content</th>
<th>Size (nm)</th>
<th>Zeta (mv)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLPE-DLPG</td>
<td>209.8 ± 2.15</td>
<td>−117.3</td>
<td></td>
</tr>
<tr>
<td>DLPE-DLPG 5% DOTMA</td>
<td>219.1 ± 0.41</td>
<td>−93.3</td>
<td></td>
</tr>
<tr>
<td>DLPE-DLPG 15% DOTMA</td>
<td>225.9 ± 3.27</td>
<td>−84.2</td>
<td></td>
</tr>
<tr>
<td>DLPE-DLPG 647-Gcase</td>
<td>193.2 ± 4.89</td>
<td>−74.1</td>
<td></td>
</tr>
<tr>
<td>DLPE-DLPG 5% DOTMA 647-Gcase</td>
<td>148.6 ± 4.85</td>
<td>−71.8</td>
<td></td>
</tr>
<tr>
<td>DLPE-DLPG 15% DOTMA 647-Gcase</td>
<td>220.1 ± 5.13</td>
<td>−79.7</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(B)</th>
<th>LNP content</th>
<th>Encapsulation (%)</th>
<th>Enzyme activity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLPE-DLPG + rGCase</td>
<td>9.98 ± 0.39</td>
<td>94 ± 1.7</td>
<td></td>
</tr>
<tr>
<td>DLPE-DLPG + 15% DOTMA + rGCase</td>
<td>8.7 ± 0.35</td>
<td>99 ± 0.2</td>
<td></td>
</tr>
</tbody>
</table>
In order to further characterize the LNPs, we analyzed the amount of encapsulated GCase as described in the Materials and Methods section. The encapsulation efficiency was 8.7% for the DOTMA-containing LNPs and 10% for the DOTMA-free LNPs (table 1). We also determined encapsulation efficiency using the fluorescent emission of an Alexa-647 labeled rGCase (647-GCase) with similar results (data not shown). These low encapsulation levels are typical levels for protein entrapment in LNPs however we wanted to determine if these low levels are enough to retain biological activity. To determine if the encapsulated rGCase retained its enzyme activity, we measured enzymatic activity of free rGCase and of the encapsulated enzyme using the 4-MUG as a substrate, as described in the Materials and Methods section. Our results demonstrated that the encapsulated enzyme retains its activity during the encapsulation process (table 1). Taken together these results demonstrate that we have constructed stable LNPs that successfully entrapped rGCase. Moreover, we have demonstrated that the encapsulation procedure did not impair the enzymatic activity of rGCase.

3.2. Internalization of rGCase containing LNPs into their target cells in the brain
As monocyte-derived cells play a pivotal role in GD and are considered as the target cells for ERT [3], we turned our attention to the resident macrophages of the brain, the microglia cells. To examine the ability of microglia cells to internalize rGCase, single cell suspension, extracted from the brains of BALB/c mice were treated for 2 h with rGCase, labeled with the 647-Alexa dye, either as free rGCase or rGCase entrapped in LNPs of different formulations. 488-Alexa labeled anti-CD11b antibody was used for microglia staining. Our results (figure 2) revealed that only microglia cells (CD11b+ cells) were able to internalize both the free and the entrapped rGCase. The fact that free rGCase could enter microglia was expected, since the recombinant enzyme is highly mannosylated, and these mannose residues recognize mannose receptor on the cells, through which it is endocytosed [35].

**Figure 1.** Transmission electron microscopy (TEM) analysis of LNPs. Representative images of: (A) DLPE/DLPG only, (B) DLPE/DLPG LNPs with rGCase (C) DLPE/DLPG which include 5% DOTMA and rGCase (D) DLPE/DLPG which include 15% DOTMA and rGCase.
3.3. LNPs entrapping rGCase delivered the enzyme into the brain via an IN administration route

Treatment of neurodegenerative diseases requires drug delivery to the brain, either by crossing an intact BBB or by bypassing it. In vivo experiments in mice were conducted to evaluate the ability of the LNPs to deliver rGCase to the brain, bypassing the BBB via IN administration. rGCase (1 mg ml$^{-1}$ of 647-Alexa-labeled enzyme) was introduced into eight week old, BALB/c female mice. The experiment was performed with 12 animals, divided into four groups. Each group consisted of three mice receiving a specific treatment: free 647-Alexa-rGCase, free LNPs, 5% DOTMA-containing LNPs with 647-Alexa-rGCase and 15% DOTMA-containing LNPs entrapping 647-Alexa-rGCase. The mice received three daily consecutive treatments via IN administration and 24 h after the final treatment distribution of rGCase in the brain was determined using the IVIS imaging system. The results (figure 3) showed that both forms (free rGCase and rGCase entrapped in the LNPs) entered the brain via the olfactory bulb, with a distinct advantage for the encapsulated rGCase over the free enzyme. Other groups have shown [36–43] that proteins can be delivered intranasally into the brain, however the same groups reported that some proteins were degraded or incised by nucleases present in the mucosa [44].

We next asked how much enzyme was delivered into the brain in a quantitative manner. We used a labeled $^3$H-rGCase to study the quantitative delivery of the free enzyme versus the entrapped enzyme. We isolated the brain after single administration (corresponding to 0.25 mg ml$^{-1}$ of free enzyme or enzyme entrapped in LNPs). We found that the amount reaching the brain with the free enzyme corresponded to 0.29% ± 0.07% ID/mg tissue whereas the amount of the entrapped enzyme corresponded to a 3.91% ± 0.3% injected dose (ID)/mg tissue. This represents a dramatic delivery of the entrapped enzyme over the free enzyme by more than 10-fold. We next asked what were the target cells that took up the enzyme in the brain.

3.4. rGCase entrapped within LNPs is delivered into microglia lysosomes

BALB/c mice were administered intranasally either with free 647-Alexa-rGCase or with 647-Alexa-rGCase, entrapped in one of the LNPs formulations, as described. Twenty-four hours after the third administration, the mice were anesthetized and following perfusion, the brains were homogenized to produce single cell suspension. Cells were stained with 488-Alexa- labeled anti-CD11b antibodies and Red DND-99 LysoTracker® to visualize lysosomes. The results (figure 4) revealed that GCase was detected only in CD11b positive cells (microglia), which are the target cells of the enzyme. Within the microglia, the rGCase was located predominately in the lysosomes. In this experiment, contrary to the ex vivo results (figure 3), there was a significant difference between
the cellular accumulation of free rGCase and rGCase entrapped in LNPs. Mice that were treated with encapsulated rGCase had a much higher amount of rGCase than mice that were treated with free rGCase. These results strongly attest that encapsulating rGCase in particles has an advantage over free recombinant enzyme when delivered into the brain.

3.5. rGCase-loaded LNPs are able to restore enzymatic activity
In order to ascertain that our delivery strategy can restore enzymatic activity in diseased cells, we incubated the LNPs with human primary skin fibroblasts that derived from severe GD patients. These cells represent the human disease and are used for examining the therapeutic potential of the delivery vehicle. The results demonstrated that only DOTMA-containing LNPs were able to elevate enzymatic activity in the cells by 30%, demonstrating that the encapsulated enzyme was endocytosed into the cells and released in such a manner that it could restore activity of the deficient GD-derived cells (table 2). Taking into consideration that fibroblasts do not possess phagocytic capabilities, the elevation in enzyme activity in the treated primary human cells is within the therapeutic range, which highlights the potential of the DOTMA LNPs as carriers of rGCase.

4. Discussion
In the present study, we tested the feasibility of introducing rGCase, encapsulated in lipid nanoparticles into the brain. We introduced intranasally free rGCase or rGCase entrapped in the LNPs and tested their ability to bypass the BBB and to be endocytosed into brain microglia cells. Our results showed that we have successfully constructed a lipid-based delivery strategy for facilitating IN delivery of rGCase into the brain’s parenchyma. We show that the ~200 nm LNPs that we constructed are of an ideal size for cellular delivery and are highly stable and homogenous. When tested ex vivo, using brain derived single cell suspensions; all formulations and the free rGCase were successful in facilitating entrance of rGCase into CD11b positive microglia cells. In vivo biodistribution assessment revealed that LNPs were superior in transporting rGCase into the brain (~4% of ID/mg tissue) compare with ~0.3% of ID/mg tissue—representing more than 10-fold difference. The LNPs transported more enzyme into the appropriate therapeutic location within the brain. Our results also demonstrated that the encapsulated GCase not only entered its target cells, the microglia, but was also detected in their lysosomes, the therapeutic site of the drug. Finally, we demonstrated that the DOTMA-based LNPs could restore enzymatic activity in GCase deficient cells derived from GD patients.

![Figure 3. Administration of rGCase into the brain. BALB/c mice were administered an IN dose of 25 μg rGCase in one of the following treatments: (A) mock (no rGCase) (B) free 647-Alexa labeled rGCase (C) LNPs with 647-Alexa labeled-rGCase (D) 5% DOTMA-containing LNPs with 647-Alexa labeled-rGCase, (E) 15% DOTMA-containing LNPs with 647-Alexa labeled-rGCase. 24 h after administration, the mice were imaged using the IVIS fluorescent imager.](image-url)
Several efforts to deliver lysosomal enzymes into the brain have been documented, these included intrathecal and intracerebroventricular administrations. Intrathecal administration was performed in animal models of mucopolysaccharidosis MPS I, II and IIIA, late infantile neuronal ceroid lipofuscinosis, and Niemann–Pick type A. The results indicated distribution of the recombinant enzyme throughout the CNS, with concomitant clearance of accumulated material within the lysosomes [45, 46]. Concerning intracerebroventricular administration, profound improvements at the histopathological and functional level have been reported in animal models of metachromatic leukodystrophy (MLD) following delivery of arylsulfatase A [47]. Intrathecal delivery in MPS I and VI is already in clinical trials [45, 48].
Table 2. GCase activity in cells incubated with different rGCase formulations. A, B, GD-derived cells (lines GM877 and GM8760, respectively) were incubated with different formulation of rGCase. Four hours later enzymatic activity was tested using a 4-MUG substrate as described in the Materials and Methods section. (A) Untreated cells, (B) Free rGCase, (C) LNPs only, (D) LNPs containing DOTMA E-LNPs entrapping rGCase F- LNPs containing DOTMA entrapping rGCase. Significance: * p < 0.01. The results are presented graphically (A) and in a table (B). The results are a summary of five experiments performed in six repeats each ± standard error.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>GM8760 cells</th>
<th>GM877 cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Untreated cells</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>(B) Free GCase</td>
<td>101.2 ± 1</td>
<td>103.6 ± 17</td>
</tr>
<tr>
<td>(C) LNPs only</td>
<td>99.4 ± 0.9</td>
<td>104.2 ± 20</td>
</tr>
<tr>
<td>(D) 15% DOTMA LNPs</td>
<td>97.1 ± 0.5</td>
<td>103.2 ± 17</td>
</tr>
<tr>
<td>(E) LNPs + GCase</td>
<td>103 ± 1.1</td>
<td>103 ± 20</td>
</tr>
<tr>
<td>(F) LNPs + 15% DOTMA + GCase</td>
<td>131.7 ± 18**</td>
<td>135 ± 12**</td>
</tr>
</tbody>
</table>

The use of nanoparticle carriers has already been investigated. Thus, liposomes containing beta-galactosidase injected into a rat tail vein were shown to penetrate the BBB and reach the lysosomes in the CNS tissue more effectively than the free enzyme [49].

The use of antibody or peptide delivery vectors capable of facilitating an enzyme entrance into the brain is also under investigation [50–53]. Thus, delivery of α-galactosidase into a mouse brain, via the BBB transferrin receptor, was evaluated by enzyme conjugation to the BBB transferrin receptor-specific monoclonal antibody in a rat [52].

The introduction of peptide-linked recombinant lysosomal rGCase into knock-out neurons resulted in the reduction of approximately 90% of the accumulated lipid substrate glucosylsphingosine [53]. Lysosome-targeted octadecyl-rhodamine B-liposomes were found to enhance the lysosomal accumulation of rGCase (velaglucerase alfa, SHIRE) for improving lysosomal delivery in GD fibroblasts [54].

An interesting issue is what increase in enzymatic activity would be needed in order for therapy to be efficient; as discussed [55, 56], a mere 1%–5% of normal intracellular enzyme activity was sufficient to correct the metabolic defect in enzyme-deficient cells.

5. Conclusion

Herein we showed that specific LNP formulation could be used to deliver rGCase to its target cells in vivo via an IN delivery route. The strategy of targeted delivery and bypassing the BBB may become a novel therapeutic modality to treat neuronopathic GD, and may serve as a platform for other lysosomal storage diseases that involve neuropathic symptoms. Moreover, this strategy may pave the way as a novel therapeutic approach to treat other diseases such as Alzheimer’s and Parkinson’s.

Acknowledgments

This work was supported in part by grants from Shire Genetics (Lexington, MA) awarded to MH and DP and by the FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative; and by The Leona M and Harry B Helmsley Nanotechnology Research Fund awarded to DP.

ORCID iDs

Dan Peer  https://orcid.org/0000-0001-8238-0673

References


